Lilly Cuts Arzoxifene Losses, Will Not File NDA
After initial results from a five-year, Phase III trial showed the drug fell short on key secondary outcome measures, Lilly has decided not to file the application with FDA.
After initial results from a five-year, Phase III trial showed the drug fell short on key secondary outcome measures, Lilly has decided not to file the application with FDA.